Author:
Kniha Kristian,Buhl Eva Miriam,Möhlhenrich Stephan Christian,Bock Anna,Hölzle Frank,Hellwig Elmar,Al-Ahmad Ali,Modabber Ali
Abstract
Abstract
Background
The aim of the present study was to assess the development of bacterial deposits and morphological parameters around dental zirconia and titanium implants compared with natural teeth during systemic bisphosphonate medication.
Materials and methods
Fifty-four rats were randomly allocated into one control group and two experimental groups (drug application of zoledronic and alendronic acid), with 18 animals in each group. After 4 weeks of drug delivery, either a zirconia or a titanium implant was immediately inserted. Microbiological analysis conducted 1 week, 8 weeks, and 12 weeks after surgery included total bacterial count and composition measurements. Samples were analyzed in a scanning electron microscope (SEM) equipped with energy-dispersive X-ray spectroscopy (EDX). Bone cell morphology was analyzed by transmission electron microscopy (TEM).
Results
One week after surgery, titanium and zirconia implants of the alendronic acid and control group showed a significantly higher bacterial count when compared to natural teeth in rats with zoledronic acid administration (p < 0.01). Less significant differences were recorded after 3 months, at which time no inter-material differences were evaluated (p > 0.05). I
n the control group, TEM analysis showed that the osteoblasts had a strongly developed endoplasmic reticulum. In contrast, the endoplasmic reticulum of the osteoblasts in drug-treated animals was significantly less developed, indicating less activity.
Conclusions
Within the limits of this study, neither implant material was superior to the other at 3-month follow-up. With regard to the treatment and complications of patients with bisphosphonates, the implant material should not be an influencing factor. Bisphosphonates can be used in the rat model to reduce not only the activity of osteoclasts but also osteoblasts of the peri-implant bone.
Funder
This study was funded by the START funding program of the medical faculty of Aachen University.
RWTH Aachen University
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg. 2009;67(5 Suppl):13–8.
2. Francis MD, Valent DJ. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. J Musculoskelet Neuronal Interact. 2007;7(1):2–8.
3. Health CAfDaTi: CADTH rapid response reports. In: Denosumab versus zoledronic acid for men with osteoporosis: a review of clinical effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health; 2016.
4. Deeks ED, Perry CM. Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs Aging. 2008;25(11):963–86.
5. Dhillon S. Zoledronic acid (Reclast((R)), Aclasta((R))): a review in osteoporosis. Drugs. 2016;76(17):1683–97.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献